Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
NCT ID: NCT01284582
Last Updated: 2012-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2011-05-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123
Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women
NCT00163163
Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand
NCT00647543
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
NCT04798430
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATH03 Group A
ATH03, 10 µg, 0.2% Alum
ATH03
4 vaccinations
ATH03 Group B
ATH03, 30 µg, 0.2% Alum
ATH03
4 vaccinations
ATH03 Group C
ATH03, 100 µg, 0.2% Alum
ATH03
4 vaccinations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATH03
4 vaccinations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High density lipoprotein cholesterol (HDLc) blood concentrations equal or below 80 mg/dl
Exclusion Criteria
18 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Affiris AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Achim Schneeberger, MD
Role: STUDY_DIRECTOR
Affiris AG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department for Clinical Pharmacology Medical University Vienna
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AFF007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.